|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||37.27 - 37.58|
|52 Week Range||29.45 - 37.79|
|Beta (3Y Monthly)||0.43|
|PE Ratio (TTM)||24.45|
|Forward Dividend & Yield||1.07 (2.88%)|
|1y Target Est||40.17|
— Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancer —
Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancerFollow-up data from pivotal phase III APHINITY study evaluating.
LEXINGTON, Mass., Nov. 15, 2019 /PRNewswire/ -- Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Promedior. With this acquisition, Roche will obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151.
Kadcyla cut the risk of disease recurrence or death by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer At three.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Polivy® (polatuzumab vedotin) in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. “People with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options – especially those who are not candidates for haematopoietic stem cell transplant,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development.
Dollar trading volume on OTC Markets topped $29 billion in October, approximately a 4.5% increase from September. For the month, total dollar volume on the OTCQX Market, the top tier of OTC Markets, was ...
Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.
Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.
AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval for the investigational medicine this year, said its SUNFISH trial demonstrated statistically significant improvements in patients aged 2-25 years with Type 2 or 3 SMA, compared to a placebo. Biogen's Spinraza, approved in 2016, lists at $750,000 in year one and $375,000 thereafter, while Novartis's Zolgensma is the costliest one-time treatment at $2.1 million.
NOBILITY phase II study showed 40% of patients treated with Gazyva plus standard of care achieved complete renal response at Week 76, compared to 18% of patients treated with.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive data from the pivotal Part 2 of SUNFISH, a study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study met its primary endpoint of change from baseline in the Motor Function Measure 32 (MFM-32) scale after one year of treatment with risdiplam, compared to placebo. Safety for risdiplam was consistent with its known safety profile and no new safety signals were identified.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive data from the pivotal Part 2 of the SUNFISH study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy (SMA). The study met its primary endpoint of change from baseline in the Motor Function Measure 32 (MFM-32) scale after one year of treatment with risdiplam, compared to placebo. Safety for risdiplam was consistent with its known safety profile and no new safety signals were identified.
The study met the primary endpoint with Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrating superiority compared to placebo plus standard of care. Patients treated with Gazyva showed increasing rates of complete renal response (CRR) from week 52 to week 76, with 40% of patients in the Gazyva group achieving CRR, compared to 18% of patients in the placebo group at week 76 (p=0.007).
Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.
Walmart reported its Q3 earnings, posting revenues of nearly $128 billion, and adjusted earnings that beat estimates. Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Julia La Roche discuss the retailer’s big win.
Dirk Van de Put, CEO of Mondelēz International (NASDAQ: MDLZ), talks to Yahoo Finance's Julia La Roche about the company's global strategy and reveals the findings of a recent study about snacking behavior.
Uber is facing a PR disaster after CEO Dara Khosrowshahi told Axios that the killing of American journalist Jamal Khashoggi was "a serious mistake" and then compared it to Uber's own "mistakes" with self-driving experiments. Yahoo Finance’s Dan Roberts, Julia La Roche and Brian Cheung discuss on YFi AM.
Facebook announced that Instagram could begin hiding "likes" on some U.S. accounts as early as this week. Users will still be able to see likes on their own posts, but those counts will not be visible to others viewing your post. Yahoo Finance’s Dan Roberts, Julia La Roche and Brian Cheung discuss on YFi AM.
Amazon third-party sellers are suspended from making sales due to an email glitch. Yahoo Finance’s Dan Roberts, Heidi Chung and Julia La Roche discuss on YFi-AM.
Zillow’s shares soar after the online real estate company beat revenue estimates for the third-quarter. Yahoo Finance’s Dan Roberts, Julia La Roche and Heidi Chung discuss on YFi AM.
Yahoo Finance's Dan Roberts, Julia La Roche, and Heidi Chung discuss the long-awaited streaming platform, Disney+, and how it will disrupt the streaming wars.